Evommune (EVMN) analyst forecast and price target
Analyst forecast
Consensus of 13 analyst ratings
Based on 4 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| UBS | Initiated Coverage | Neutral | $8.00 | Oct 12, 2026 |
| HC Wainwright & Co. | Maintained | Neutral | — | Sep 9, 2026 |
| RBC Capital | Maintained | Outperform | $21.00 from $29.00 | Sep 9, 2026 |
| Leerink Partners | Maintained | Outperform | $22.00 from $28.00 | Sep 9, 2026 |
| Needham | Initiated Coverage | Buy | $28.00 | Aug 26, 2026 |
| RBC Capital | Maintained | Outperform | $29.00 from $30.00 | Aug 7, 2026 |
| HC Wainwright & Co. | Maintained | Neutral | — | Aug 3, 2026 |
| HC Wainwright & Co. | Downgraded | Buy → Neutral | — | Jun 30, 2026 |
| Morgan Stanley | Maintained | Overweight | $26.00 from $55.00 | Jun 30, 2026 |
| William Blair | Downgraded | Outperform → Market Perform | — | Jun 29, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $50.00 | May 26, 2026 |
| Morgan Stanley | Maintained | Overweight | $55.00 from $54.00 | May 11, 2026 |
| RBC Capital | Maintained | Outperform | $48.00 | Apr 10, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $50.00 from $65.00 | Mar 18, 2026 |
| Clear Street | Initiated Coverage | Buy | $53.00 | Mar 18, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $65.00 from $35.00 | Feb 10, 2026 |
| Oppenheimer | Initiated Coverage | Outperform | $42.00 | Jan 22, 2026 |
| Raymond James | Initiated Coverage | Strong Buy | $40.00 | Jan 8, 2026 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $35.00 | Jan 6, 2026 |
| Leerink Partners | Initiated Coverage | Outperform | $42.00 | Dec 1, 2025 |
Frequently asked questions
What is the price target for EVMN stock?
The average 12-month analyst price target for Evommune (EVMN) is $19.75, with a high estimate of $28.00 and a low of $8.00, across 4 analysts.
Is EVMN a buy, sell, or hold?
Analysts covering Evommune currently average a Buy rating: 10 buy, 3 hold and 0 sell, from 13 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for EVMN?
The average price target of $19.75 implies 235.60% upside from the last price of $5.89.
What is the latest analyst rating on EVMN?
On Oct 12, 2026, UBS initiated coverage of Evommune at Neutral with a price target of $8.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.